Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

University of Minnesota Researchers Find Evidence of Genetic Link to Breast Density

June 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 6
Volume 11
Issue 6

Researchers at the University of Minnesota Cancer Center have found evidence that mamographic breast density, a measure of the relative proportions of fat, connective tissue, and glandular epithelial tissue in the breast that is a strong, independent

Researchers at the University of Minnesota Cancer Center have foundevidence that mamographic breast density, a measure of the relative proportionsof fat, connective tissue, and glandular epithelial tissue in the breastthat is a strong, independent predictor of breast cancer risk, is geneticallyinfluenced. The study, published in the April 16th Journal of the NationalCancer Institute, also suggests that 12% of the population has a geneticmutation that results in a breast density twice that of women without themutation.

"It isn't known how high breast density increases the risk of breastcancer," said lead investigator Thomas Sellers, associate professorof epidemiology and associate director of the Cancer Center. "Butthe risk is considered second only to the risk incurred by mutations inthe BRCA1 and BRCA2 genes."

The researchers obtained routine mammograms and a variety of health-relateddata from 1,370 women from 258 different Minnesota families. The studypopulation included 65 mother-daughter pairs and 275 sister-sister pairs.All of the women were related, either genetically or by marriage, to anoriginal group of 544 breast cancer patients seen at the University ofMinnesota between 1944 and 1952. Sellers and colleagues are studying thesefamilies as part of the Breast Cancer Family Cohort study.

Breast Density Partly Modifiable

Sellers says that the study is significant because the researchers wereable to separate out other risk factors, such as waist-to-hip ratio, physicalactivity, hormone replacement therapy, and number of live births, to detecta Mendelian dominant inheritance pattern (a pattern where only one copyof the mutated gene is necessary to transfer the trait to offspring). Theywere unable, however, to completely eliminate the possibility of a recessivepattern, which would require more than one copy of a gene to produce atrait. However, if breast density is, indeed, controlled by a dominantgene, about 12% of the population would be expected to carry a form ofthe gene that results in a breast density about twice that of the restof the population. "The good news is that while breast density riskfactor is partly genetic, it's also shaped by the environment, and so canbe modified," Sellers said.

In previous studies, Sellers and colleagues have reported on potentialrisk factors for breast cancer, including waist-to-hip ratio, fat in thediet, and the connection between breast cancer in women and prostate cancerin men. These finding stem from the Iowa Women's Study, an ongoing healthstudy of more than 40,000 women in Iowa.

Articles in this issue

Use of Adjuvent Analgesics Profiled at Pain Conference
Chromosomal Changes Linked to Family History of Lung Cancer
Bacterial Infection in Patients With Cancer: Focus on Prevention
Docetaxel in Combined Modality Therapy for Breast Cancer
Role of Diet in Cancer Hard to Study, Expert Says
Anti-HIV Effects of Viracept Persist During Long Periods of Combination Therapy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
Related Content

The trial had an estimated enrollment of 50 patients who received oral TT125-802 as a single agent.

FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC

Tim Cortese
August 28th 2025
Article

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
August 28th 2025
Podcast

The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
August 28th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 28th 2025
Podcast

Results came from the pilot, open-label, phase 2 QUILT-3.078 trial (NCT06061809) that evaluated nogapendekin alfa inbakicept with PD-L1 t-haNK and bevacizumab in patients with recurrent or progressive glioblastoma.

Nogapendekin Alfa Inbakicept Combo Yields Disease Control in Glioblastoma

Tim Cortese
August 28th 2025
Article

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
August 28th 2025
Article
Related Content

The trial had an estimated enrollment of 50 patients who received oral TT125-802 as a single agent.

FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC

Tim Cortese
August 28th 2025
Article

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Beyond the BEP: A Deep Dive into Testicular Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Nabil Adra, MD
August 28th 2025
Podcast

The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
August 28th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 28th 2025
Podcast

Results came from the pilot, open-label, phase 2 QUILT-3.078 trial (NCT06061809) that evaluated nogapendekin alfa inbakicept with PD-L1 t-haNK and bevacizumab in patients with recurrent or progressive glioblastoma.

Nogapendekin Alfa Inbakicept Combo Yields Disease Control in Glioblastoma

Tim Cortese
August 28th 2025
Article

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
August 28th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.